scholarly journals New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non–Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy

2010 ◽  
Vol 195 (3) ◽  
pp. W221-W228 ◽  
Author(s):  
Mizuki Nishino ◽  
David M. Jackman ◽  
Hiroto Hatabu ◽  
Beow Y. Yeap ◽  
Leigh-Anne Cioffredi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Small Cell Lung Cancer ◽  
Solid Tumors ◽  
Tumor Response ◽  
Evaluation Criteria ◽  
Small Cell ◽  
Response Evaluation ◽  
Small Cell Lung ◽  
Response Evaluation Criteria

Stabilization of the disease as an important factor in the evaluation of the effectiveness of treatment and prognosis of survival for cancer patients

2016 ◽  
Vol 21 (1-2) ◽  
pp. 6-10
Author(s):  
Mark B. Bychkov ◽  
S. G Bagrova ◽  
T. D Karpenko
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Solid Tumors ◽  
Cell Lung Cancer ◽  
Evaluation Criteria ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cancer Breast ◽  
Slight Growth ◽  
The One

Currently, the effectiveness of treatment is assessed by Response Evaluation Criteria In Solid Tumors (RECIST) criteria. The stabilization of the disease is the one of the results of the treatment. This term means a slight growth or regression of the tumor without the appearance of new lesions, when it is impossible to assign these changes neither to the progression of the disease nor to partial regression, but in any case stabilization of disease is evaluated as ineffective treatment. But the stabilization of the disease often leads to the improvement of the quality of life, slowdown in the growth of the tumor and metastasis and thereby to the win in terms of life expectancy. The purpose of the study. A study of the concept of ‘stabilization of the disease ’ as a criterion that determines the control of tumor growth. Methods. There was performed an analysis of various scientific works on the study of the efficiency of the treatment of solid tumors: ovarian cancer, small-cell lung cancer (SCLC), non small-cell lung cancer (NSCLC), colon cancer, prostate cancer, breast cancer. Conclusion. Stabilization of the disease is an important criterion for the evaluation of the antitumor treatment in patients and has the important prognostic value.

scholarly journals Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung

2021 ◽  
Vol 12 (6) ◽  
Author(s):  
Walter Z. Wang ◽  
Konstantin Shilo ◽  
Joseph M. Amann ◽  
Alyssa Shulman ◽  
Mohammad Hojjat-Farsangi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lines ◽  
Cell Lung Cancer ◽  
Therapeutic Target ◽  
Small Cell ◽  
Orphan Receptor ◽  
Small Cell Lung ◽  
Sclc Patient

AbstractSmall cell lung cancer (SCLC) remains a deadly form of cancer, with a 5-year survival rate of less than 10 percent, necessitating novel therapies. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncofetal protein that is emerging as a therapeutic target and is co-expressed with BCL2 in multiple tumor types due to microRNA coregulation. We hypothesize that ROR1-targeted therapy is effective in small cell lung cancer and synergizes with therapeutic BCL2 inhibition. Tissue microarrays (TMAs) and formalin-fixed paraffin-embedded (FFPE) SCLC patient samples were utilized to determine the prevalence of ROR1 and BCL2 expression in SCLC. Eight SCLC-derived cell lines were used to determine the antitumor activity of a small molecule ROR1 inhibitor (KAN0441571C) alone and in combination with the BCL2 inhibitor venetoclax. The Chou-Talalay method was utilized to determine synergy with the drug combination. ROR1 and BCL2 protein expression was identified in 93% (52/56) and 86% (48/56) of SCLC patient samples, respectively. Similarly, ROR1 and BCL2 were shown by qRT-PCR to have elevated expression in 79% (22/28) and 100% (28/28) of SCLC patient samples, respectively. KAN0441571C displayed efficacy in 8 SCLC cell lines, with an IC50 of 500 nM or less. Synergy as defined by a combination index of <1 via the Chou-Talalay method between KAN0441571C and venetoclax was demonstrated in 8 SCLC cell lines. We have shown that ROR1 inhibition is synergistic with BCL2 inhibition in SCLC models and shows promise as a novel therapeutic target in SCLC.

scholarly journals Surgical choice of non-small cell lung cancer with unexpected pleural dissemination intraoperatively

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Junjie Hu ◽  
Yan Chen ◽  
Xinsheng Zhu ◽  
Qiang Ma ◽  
Jing Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Small Cell Lung Cancer ◽  
Distant Metastasis ◽  
Survival Benefit ◽  
Tumor Resection ◽  
Small Cell ◽  
Small Cell Lung ◽  
Systematic Lymphadenectomy ◽  
Cox Analysis

Abstract Background Whether patients with non-small cell lung cancer (NSCLC) with unexpected pleural dissemination (UPD) could get survival benefit from tumor resection remained controversial. Methods Totally, 169 patients with NSCLC with UPD were included between 2012 and 2016. Patients were divided into the tumor resection and open-close group. Progression-free survival (PFS) and overall survival (OS) were compared with a log-rank test. The multivariable Cox analysis was applied to identify prognostic factors. Results Sixty-five patients received open-close surgery and 104 patients underwent main tumor and visible pleural nodule resection. Tumor resection significantly prolonged OS (hazard ratio [HR]: 0.408, P < 0.001), local PFS (HR: 0.283, P < 0.001), regional PFS (HR: 0.506, P = 0.005), and distant metastasis (HR: 0.595, P = 0.032). Multivariable Cox analysis confirmed that surgical method was an independent prognostic factor for OS, local PFS and regional PFS, except distant metastasis. Subgroup analyses indicated that tumor resection could not improve OS in the patients who received targeted therapy (HR: 0.649, P = 0.382), however, tumor resection was beneficial for the patients who received adjuvant chemotherapy alone (HR: 0.322, P < 0.001). In the tumor resection group, lobectomy (HR: 0.960, P = 0.917) and systematic lymphadenectomy (HR: 1.512, P = 0.259) did not show survival benefit for OS. Conclusions Main tumor and visible pleural nodule resection could improve prognosis in patients with UPD who could not receive adjuvant targeted therapy. Sublobar resection without systematic lymphadenectomy may be the optimal procedure.

Sign in / Sign up

Export Citation Format

Share Document